Biobot Analytics

biobot.io →

-76%

est. 2Y upside i

HealthcareSeries A

Population health analytics powered by wastewater.

Rank

#2938

Sector

Public Health Technology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Biobot Analytics operates in a promising public health technology niche with a moderate moat and recent significant government contracts, like the one with the White House ONDCP.

Last updated: March 10, 2026

Bull (15%)+250%

Biobot leverages its recent White House ONDCP contract to expand rapidly into new government agencies and international markets, becoming the dominant player in wastewater intelligence for public health. Revenue scales to over $100M by 2028, justifying a $210M+ valuation at a 2.5x revenue multiple, significantly increasing common stock value.

Base (45%)+50%

Biobot continues to grow steadily, maintaining its partnerships with the CDC and other public health departments. It expands its offerings beyond infectious diseases and illicit drugs into broader public health indicators. Revenue reaches $25M-$30M by 2028, leading to a $90M valuation, providing moderate returns for common stock after investor preferences.

Bear (40%)-80%

Dominant incumbents like Verily or large environmental testing labs aggressively enter the wastewater intelligence market, commoditizing Biobot's core offerings. The company struggles to secure new large contracts, and the prior employee reduction signals ongoing operational challenges. Revenue growth stalls, leading to a down round or acquisition at a valuation of $12M or less, wiping out most or all common stock value due to liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Investors hold $43M in liquidation preferences ahead of common stock. In an exit at or below $43M, common stock holders would receive nothing.

Dilution Risk

high

Given the current revenue and market opportunity, Biobot will likely require additional funding rounds to scale, leading to further dilution for existing equity holders.

Secondary Liquidity

none

As a Series A company, there is currently no active secondary market or tender offers for Biobot Analytics' shares.

Questions to Ask at the Interview

Strategic questions based on Biobot Analytics's data — designed to show you've done your homework.

1
“Given Verily Life Sciences' presence in wastewater monitoring, what is Biobot's long-term strategy to differentiate and maintain its competitive moat, particularly in securing large government contracts?”
2
“The company experienced a significant employee count decrease from 2022 to 2023. Can you elaborate on the reasons behind this and how the company plans to manage talent acquisition and retention for future growth, especially after securing the ONDCP contract?”
3
“With $43M in total funding and an estimated current valuation of $60M, there's a substantial liquidation preference for investors. How does Biobot plan to create meaningful equity value for common stock holders, and what is the anticipated timeline for a liquidity event?”

Community

Valuation Sentiment

Our model estimates -76% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.